

**Seventh EUCAST steering committee meeting
Summary of minutes of meeting in Prague, Czech Republic, 30 April 2004**

Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Fred Goldstein	FG	SFM	France
Dr Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Dr Ingrid Nilsson-Ehle	IN-E	SRGA	Sweden
Dr Martin Steinbakk	MS	NWGA	Norway
Dr Pavla Urbaskova	PU	EUCAST	Czech Republic
Dr Alkiviadis Vatopoulos	AV	EUCAST	Greece

Apologies

Dr Anders Österlund	AO	SRGA	Sweden
Dr Arne Rodloff	AR	DIN	Germany

1	Chairman's welcome and report
2	Minutes of meeting of 3 February 2004 accepted as a correct record.
3	<p>Matters arising from minutes of 3 February 2004 Declarations of interest were noted. The current form would be reviewed next year. Information on interests must be requested in writing and will be given in writing.</p> <p>Comments on proposed breakpoints and Steering Committee responses to be updated.</p> <p>Instructions for access to EUCAST websites have been redistributed and a bug fixed.</p> <p>All expense claims be sent via GK for Chairman's approval.</p> <p>Draft procedure for setting breakpoints is on the EUCAST public website for comment</p> <p>Response sent to letter from Bayer</p>
4	Aminoglycoside breakpoints. No comments on proposed breakpoints had been received. Breakpoints finalised.
5	Linezolid breakpoints No comments on proposed breakpoints had been received. Breakpoints finalised.
6	<p>Glycopeptide breakpoints Comments received from Aventis were discussed. Agreed to include a footnote on referring to national methods for recommendations. Breakpoints finalised.</p>
7	<p>Quinolone breakpoints Agreed that when assessing any breakpoints, the pharmacokinetic data provided by companies should be interpreted as appropriate by the Steering Committee and this interpretation may be different from that provided by the company.</p> <p>The pharmacodynamic data in relation to moxifloxacin and levofloxacin in relation to pneumococci were discussed and breakpoints agreed.</p> <p>Agreed footnote 1 to the quinolone table should indicate that the data on <i>Salmonella</i> and ciprofloxacin relate mainly to <i>S typhi</i>.</p>

	Breakpoints finalised.
8	Carbapenem breakpoints. Background data were reviewed -additional data are needed.
9	Cephalosporin breakpoints Some MIC data have been received. There were preliminary discussions on breakpoints.
10	Agreed that a table template for comments on any breakpoints, with space for the Steering Committee response, would be posted on the website.
11	Rationale documents The format was discussed. All would be involved in adding to rationale documents. Agreed that European SPCs would be source of pk/pd data unless not available or unacceptable.
12	EUCAST Committee membership General Committee members have been asked to confirm membership of the General Committee. Applications to be General Committee representatives on the Steering Committee were received on behalf of Olga Stetsiouk (Russia) and Francisco Soriano (Spain) and these had been approved at the ESCMID Board meeting on 29 April 2004.
13	As this was their last meeting, PU and AV were thanked for their contributions and good humour. CEN/ISO Reported that the joint meeting of CEN and ISO committees on 22 April 2004 had been very positive and good progress had been made towards a reference broth microdilution method.
14	EMEA An EMEA Standard Operating Procedure is being prepared with involvement of EUCAST in setting breakpoints for new agents by both the centralised and mutual recognition pathways. Noted that EMEA had no jurisdiction over old breakpoints, but harmonised EUCAST breakpoints will be considered at 5-year re-evaluations.
15	ECCMID meeting Prague
15.1	The EUCAST General Committee meeting and symposium would both be held on 3 May 2004.
16	Noted that national representatives were expected to be routinely involved with antimicrobials Finance The DG-SANCO grant would run from 1 May 2004 to 30 April 2007.
17	EUCAST documents Nothing new to report.
18	EARSS EARSS Advisory Board and Country Representative meetings had been held recently. An application has been made by a consortium of UKNEQAS, EUCAST, EARSS and the Polish Centre for QC to DG-SANCO for funds for an EQA scheme for national reference laboratories.
19	Any other business Daptomycin breakpoints would be considered at the September 2004 meeting. Tigecycline breakpoints might also be considered this year.
20	Will need to consider relationships with networks which have set their own breakpoints (eg <i>Neisseria gonorrhoeae</i> , <i>Neisseria meningitidis</i>), with the EMA and with the new European Centre for Disease Prevention and Control. Next meetings 6-7 September 2004 Munich. 22-23 November, venue to be decided. Early February 2005 if required. 31 March-1 April 2005, Prior to ECCMID 2005, Copenhagen

Ratified minutes summary 7 September 2004
Prepared by DB and GK